- Home
- PHVS vs BHC Comparison
PHVS vs BHC Comparison
Compare PHVS & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHVS | BHC |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PHVS | BHC |
|---|---|---|
| Price | $27.65 | $5.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 3 |
| Target Price | ★ $41.82 | $8.33 |
| AVG Volume (30 Days) | 204.7K | ★ 1.1M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 423.08 |
| EPS | N/A | ★ 0.42 |
| Revenue | N/A | ★ $8,724,000,000.00 |
| Revenue This Year | N/A | $4.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.49 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.51 | $4.41 |
| 52 Week High | $30.24 | $8.69 |
Technical Indicators
Market Signals| Indicator | PHVS | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 49.07 |
| Support Level | $24.55 | $5.52 |
| Resistance Level | $28.35 | $5.62 |
| Average True Range (ATR) | 1.30 | 0.18 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 46.28 | 44.23 |
Price Performance
Historical ComparisonAbout PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.